OTCMKTS:TRUMY - TERUMO CORP/ADR Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$28.90 +0.28 (+0.98 %)
(As of 04/22/2019 02:53 PM ET)
Previous Close$28.62
Today's Range$28.90 - $28.90
52-Week Range$25.5950 - $31.9150
Volume435 shs
Average Volume578 shs
Market CapitalizationN/A
P/E Ratio26.27
Dividend Yield0.35%
Beta0.38
Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. It provides products for use in cardiothoracic surgery, interventional procedure, and medicine transfusion. The company offers vascular intervention devices, such as introducer sheathes, guide wires, angiographic catheters, and radial artery compression devices; therapeutic devices; and intravascular imaging systems, including optical frequency domain imaging and intravascular ultrasound systems. It also provides interventional oncology devices, such as micro balloon catheters, micro catheters and guide wires, and drug-elutable beads; cardiopulmonary bypass systems comprising oxygenators with integrated arterial filters, heart-lung machines, and devices for operating a centrifugal pumps for extracorporeal life support systems; and thoracic vascular and abdominal vascular grafts. In addition, the company offers infusion systems; closed anticancer drug infusion systems; blood glucose monitoring systems, digital blood pressure monitors, digital thermometers, pulse oximeters, walking intensity monitors, body composition monitors, and HR joint meter/monitors; sprayable adhesion barrier gels; analgesics; pharmaceuticals and nutritional supplements; and peritoneal dialysis devices and fluids. Further, it provides other consumer healthcare products, such as basal thermometers, fall prevention products, oral care products, and urine test strips; and blood bag systems with leukocyte reduction filters, automated blood collection and blood component processing systems, pathogen reduction technology systems, centrifugal apheresis systems, cell expansion systems, and autologous cell processing devices. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.

Receive TRUMY News and Ratings via Email

Sign-up to receive the latest news and ratings for TRUMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical & hospital equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:TRUMY
Previous SymbolNASDAQ:TRUMY
CUSIPN/A
CIKN/A
Phone813-3374-8111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.31 billion
Cash Flow$1.5993 per share
Book Value$6.52 per share

Profitability

Net Income$821.65 million

Miscellaneous

Employees23,319
Next Earnings Date5/8/2019 (Estimated)
OptionableNot Optionable

TERUMO CORP/ADR (OTCMKTS:TRUMY) Frequently Asked Questions

What is TERUMO CORP/ADR's stock symbol?

TERUMO CORP/ADR trades on the OTCMKTS under the ticker symbol "TRUMY."

When is TERUMO CORP/ADR's next earnings date?

TERUMO CORP/ADR is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for TERUMO CORP/ADR.

Has TERUMO CORP/ADR been receiving favorable news coverage?

News stories about TRUMY stock have been trending somewhat positive on Monday, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. TERUMO CORP/ADR earned a news impact score of 1.7 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the next few days.

Who are some of TERUMO CORP/ADR's key competitors?

What other stocks do shareholders of TERUMO CORP/ADR own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TERUMO CORP/ADR investors own include BTG (BTG), AbbVie (ABBV), Laurentian Bank of Canada (LB), Wirecard (WDI), Siemens Healthineers (SHL), Stroeer SE & Co KGaA (SAX), Krones (KRN), Umicore (UMI), Inditex (ITX) and Luxottica Group (LUX).

Who are TERUMO CORP/ADR's key executives?

TERUMO CORP/ADR's management team includes the folowing people:
  • Mr. David Brian Perez, Sr. Exec. Officer & Director (Age 60)
  • Mr. Shinjiro Sato, Pres, CEO & Director
  • Ryo Nishihata, Sr. Exec. Officer and Chief Accounting & Financial Officer
  • Mr. Hiroaki Kasukawa, CTO & Exec. Officer
  • Katsuya Takeuchi, Chief Information Officer & Exec. Officer

How do I buy shares of TERUMO CORP/ADR?

Shares of TRUMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TERUMO CORP/ADR's stock price today?

One share of TRUMY stock can currently be purchased for approximately $28.90.

What is TERUMO CORP/ADR's official website?

The official website for TERUMO CORP/ADR is http://www.terumo.com.

How can I contact TERUMO CORP/ADR?

TERUMO CORP/ADR's mailing address is 2-44-1 Hatagaya Shibuya-ku, Tokyo M0, 151-0072. The company can be reached via phone at 813-3374-8111 or via email at [email protected]


MarketBeat Community Rating for TERUMO CORP/ADR (OTCMKTS TRUMY)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  127
MarketBeat's community ratings are surveys of what our community members think about TERUMO CORP/ADR and other stocks. Vote "Outperform" if you believe TRUMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRUMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel